1610353-18-8

1610353-18-8 structure
1610353-18-8 structure
  • Name: Brazikumab
  • Chemical Name: Brazikumab
  • CAS Number: 1610353-18-8
  • Molecular Formula:
  • Molecular Weight:
  • Catalog: Signaling Pathways Immunology/Inflammation Interleukin Related
  • Create Date: 2023-01-30 15:02:47
  • Modify Date: 2024-04-11 22:43:06
  • Brazikumab (AMG 139) is a human IgG2 monoclonal antibody, selectively binds the p19 subunit of IL-23, with a KD of 0.138 nM for human IL-23. Brazikumab can be used for the research of Crohn's disease[1].

Name Brazikumab
Description Brazikumab (AMG 139) is a human IgG2 monoclonal antibody, selectively binds the p19 subunit of IL-23, with a KD of 0.138 nM for human IL-23. Brazikumab can be used for the research of Crohn's disease[1].
Related Catalog
Target

IL-23:0.138 nM (Kd)

In Vitro Brazikumab inhibits the binding of both recombinant and native IL-23 to its receptors stably expressed in COS cells with IC50s of 188 and 284 pM, respectively[1]. Brazikumab inhibits the production of IFN-γ in NK cells stimulated by human native or recombinant IL-23 (in association with IL-18) with IC50s of 238 and 93 pM, respectively[1].
References

[1]. Currò D, et, al. Frontiers in Drug Research and Development for Inflammatory Bowel Disease. Front Pharmacol. 2017 Jun 23;8:400.  

[2]. Al-Bawardy B, et, al. Novel and Emerging Therapies for Inflammatory Bowel Disease. Front Pharmacol. 2021 Apr 14;12:651415.  

No Any Chemical & Physical Properties